Intranuclear inclusions of polyQ-expanded ATXN1 sequester RNA molecules.

RNA sequestration RNA-seq ataxin-1 intranuclear inclusion bodies protein–protein interaction network ribosome spinocerebellar ataxia type 1

Journal

Frontiers in molecular neuroscience
ISSN: 1662-5099
Titre abrégé: Front Mol Neurosci
Pays: Switzerland
ID NLM: 101477914

Informations de publication

Date de publication:
2023
Historique:
received: 22 08 2023
accepted: 16 11 2023
medline: 21 12 2023
pubmed: 21 12 2023
entrez: 21 12 2023
Statut: epublish

Résumé

Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disease caused by a trinucleotide (CAG) repeat expansion in the ATXN1 gene. It is characterized by the presence of polyglutamine (polyQ) intranuclear inclusion bodies (IIBs) within affected neurons. In order to investigate the impact of polyQ IIBs in SCA1 pathogenesis, we generated a novel protein aggregation model by inducible overexpression of the mutant ATXN1(Q82) isoform in human neuroblastoma SH-SY5Y cells. Moreover, we developed a simple and reproducible protocol for the efficient isolation of insoluble IIBs. Biophysical characterization showed that polyQ IIBs are enriched in RNA molecules which were further identified by next-generation sequencing. Finally, a protein interaction network analysis indicated that sequestration of essential RNA transcripts within ATXN1(Q82) IIBs may affect the ribosome resulting in error-prone protein synthesis and global proteome instability. These findings provide novel insights into the molecular pathogenesis of SCA1, highlighting the role of polyQ IIBs and their impact on critical cellular processes.

Identifiants

pubmed: 38125008
doi: 10.3389/fnmol.2023.1280546
pmc: PMC10730666
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1280546

Informations de copyright

Copyright © 2023 Gkekas, Vagiona, Pechlivanis, Kastrinaki, Pliatsika, Iben, Xanthopoulos, Psomopoulos, Andrade-Navarro and Petrakis.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Ioannis Gkekas (I)

Centre for Research and Technology Hellas, Institute of Applied Biosciences, Thessaloniki, Greece.
Laboratory of Pharmacology, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Aimilia-Christina Vagiona (AC)

Faculty of Biology, Johannes Gutenberg University Mainz, Mainz, Germany.

Nikolaos Pechlivanis (N)

Centre for Research and Technology Hellas, Institute of Applied Biosciences, Thessaloniki, Greece.

Georgia Kastrinaki (G)

Aerosol and Particle Technology Laboratory, Centre for Research and Technology Hellas, Chemical Process and Energy Resources Institute, Thessaloniki, Greece.

Katerina Pliatsika (K)

Centre for Research and Technology Hellas, Institute of Applied Biosciences, Thessaloniki, Greece.
Laboratory of Pharmacology, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Sebastian Iben (S)

Department of Dermatology and Allergic Diseases, University of Ulm, Ulm, Germany.

Konstantinos Xanthopoulos (K)

Centre for Research and Technology Hellas, Institute of Applied Biosciences, Thessaloniki, Greece.
Laboratory of Pharmacology, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Fotis E Psomopoulos (FE)

Centre for Research and Technology Hellas, Institute of Applied Biosciences, Thessaloniki, Greece.

Miguel A Andrade-Navarro (MA)

Faculty of Biology, Johannes Gutenberg University Mainz, Mainz, Germany.

Spyros Petrakis (S)

Centre for Research and Technology Hellas, Institute of Applied Biosciences, Thessaloniki, Greece.

Classifications MeSH